Accelerated Fractionation Plus Chemotherapy Versus Conventionally Fractionated Radiochemotherapy for Unresectable Head-and-Neck Cancer
نویسندگان
چکیده
منابع مشابه
Altered fractionation for head and neck cancer.
A conventional course of radiation for squamous cell carcinoma in the United States is generally 70 Gy in 7 weeks, with a once-daily dose of 1.8 to 2 Gy. This schedule has a modest success rate in curing head and neck cancer. The past several decades have seen numerous investigations into altering this schedule to optimize the results of radiation. Two approaches, founded on radiobiologic princ...
متن کاملPlatinum-based chemotherapy plus cetuximab in head and neck cancer.
BACKGROUND Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. METHODS We randomly assigned 220 of 442 eligible patients with untreated recurrent ...
متن کاملAltered Fractionation for Head and Neck Cancer
Delivery of therapeutic radiation in multiple sessions, or fractions, has been practiced since the discovery of radiation’s potential to cure malignancies. Initially, this was done out of practical necessity: Radiation was delivered at a low dose rate, and the treatment sessions had to be repeated to obtain the desired effect. Technologic improvements eventually allowed for treatments in one se...
متن کاملHead and neck cancer: altered fractionation schedules.
Local control is paramount in the treatment of localized advanced head and neck cancer. Standard radiotherapy cures a high percentage of early tumors--more than 80% of the early laryngeal tumors--but fewer of the advanced tumors. Attempts have therefore been made to improve the therapeutic ratio by: A) hyperfractionation: reducing the dose per fraction to reduce late morbidity; the total dose i...
متن کاملOutpatient oral chemotherapy with S-1 for unresectable or distant metastatic head and neck cancer.
BACKGROUND This retrospective study evaluated the efficacy and safety of S-1 chemotherapy for unresectable or distant metastatic head and neck cancer. S-1 is an oral anticancer agent containing a combination of 2 modulators and tegafur, which is a pro-drug of 5-fluorouracil. PATIENTS AND METHODS S-1 was orally administered to 27 patients with unresectable and/or distant metastatic head and ne...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Anticancer Research
سال: 2021
ISSN: 0250-7005,1791-7530
DOI: 10.21873/anticanres.14840